Publications

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in cardiac surgery from the perspective of a US hospital. Abstract EE734, ISPOR EU 2023.

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in acute hypertension from the perspective of a US hospital. Abstract EE125, ISPOR EU 2023.

Bean K, Miller B, Jensen I, Howle K, Wilds A, Walz M, et al. The societal costs of metachromatic leukodystrophy (MLD) in the United States. Abstract EE547, ISPOR EU 2023.

Miller B, Russel-Szymczyk M, Jensen I, Shah A, Alexopoulos T, Herbert A, et al. Cost-consequence of cladribine tablets for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in the UK. Abstract EE658, ISPOR EU 2023.

Davies S, Boller E, Beaubrun A, Miller C, Jensen I. A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV Plus for the diagnosis of viral respiratory infections from a US health plan perspective. Abstract ID309. AMP 2023 Annual Meeting & Expo.

Bylsma LC, Pundole X, Ju C-H, Hooda N, Movva N, Elkhouly E, et al. 2023. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. Target Oncol 18(6):821-835; doi: 10.1007/s11523-023-01008-x. PMID: 37930513.

Franklin M, Emden MR, Bauer E, Nguyen AT, Sacks N, Kawamatsu S, Kawano Y,  Mitrani-Gold FS, Joshi AV, Ju S, Preib MT. Prevalence of acute uncomplicated cystitis in Japan. Poster presentation, IDWeek, October 2023.

Franklin M, Emden MR, Kautz S, Nguyen AT, Sacks NC, Ju S, Mitrani-Gold FS, Joshi AV, Preib MT. Cost burden of patients with oral antibiotic treatment failure for uncomplicated urinary tract infection in the United States. Poster presentation, IDWeek, October 2023.

Pastula S, Bylsma LC, Movva N, Rege S, Lewis RJ, Fryzek JP. 2023. Scoping review of indices to monitor community health. Open Science Framework.

Nelson CB, Jiang X, Suh M, Fryzek J. Prevention of respiratory syncytial virus hospitalizations (RSVH) in US infants who paid through Medicaid would have a greater benefit for Black, Hispanic, Asian/Pacific Islander, Native American and Other race/ethnicity infants, and have a substantial impact on overall RSVH burden and related costs: Rates of respiratory syncytial virus hospitalization (RSVH) among US infants by race/ethnicity and insurance payer, NIS 2018-2020. Poster 1536169, IDWeek 2023, Boston, MA, October 2023.